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Abstract
Patients having the nephrogenic syndrome of inappropriate antidiuresis present either the R137C or R137L V2 mutated
receptor. While the clinical features have been characterized, the molecular mechanisms of functioning of these two
mutants remain elusive. In the present study, we compare the pharmacological properties of R137C and R137L mutants
with the wild-type and the V2 D136A receptor, the latter being reported as a highly constitutively active receptor. We have
performed binding studies, second messenger measurements and BRET experiments in order to evaluate the affinities of
the ligands, their agonist and antagonist properties and the ability of the receptors to recruit b-arrestins, respectively. The
R137C and R137L receptors exhibit small constitutive activities regarding the Gs protein activation. In addition, these two
mutants induce a constitutive b-arrestin recruitment. Of interest, they also exhibit weak sensitivities to agonist and to
inverse agonist in term of Gs protein coupling and b-arrestin recruitment. The small constitutive activities of the mutants
and the weak regulation of their functioning by agonist suggest a poor ability of the antidiuretic function to be adapted to
the external stimuli, giving to the environmental factors an importance which can explain some of the phenotypic variability
in patients having NSIAD.
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Introduction
Variouspathologieshavebeen described astheconsequence ofG
protein-coupled receptor (GPCR) mutations [1]. X-linked congen-
ital nephrogenic diabetes insipidus (cNDI) has thus been described
as a loss of function of the vasopressin (AVP) V2 receptor, and more
than 200mutationsofthereceptor gene have been identified [2]. By
contrast to this well characterized pathology, only few patients with
nephrogenic syndrome of inappropriate antidiuresis (NSIAD) have
been reported [3–8]. These patients exhibit hyponatremia, and
inappropriate elevated urinary osmolality often associated to low
plasma vasopressin levels. Though the clinical and biological
features have been described through 9 case reports, much less is
known regarding the pharmacological properties of the mutated
receptors. In the original study, two mutations, R137C and R137L,
responsible for NSIAD and localized in the highly conserved DRY/
C motif in GPCR class A have been reported to confer to the
receptor a G protein constitutive activity [3].
Here we observed that the G protein constitutive activity is
associated to a constitutive recruitment of arrestins, the recruit-
ment of b-arrestins being involved in receptor-G protein
desensitization as well as in promoting the activation of G
protein-independent signaling pathways [9–11]. These two
signalling pathways are weakly regulated by AVP and inverse
agonist. As such these two mutants differ from the D136A mutant,
a constitutive V2 receptor identified only in heterologous
expression systems and which exhibit strong constitutive and
regulated activities [12].
Results
The R137C and R137L mutants when expressed in COS-7
cells exhibited a significant constitutive activity when measuring
the intracellular cAMP accumulation. The basal cAMP produc-
tion normalized to the number of cell surface receptors determined
by ligand binding was significantly higher in cells expressing
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8383R137C or R137L receptors compared to cells expressing the WT
receptor (Figure 1a), confirming the constitutive activity measured
by the indirect gene reporter assay [3]. These constitutive activities
remained of small amplitude compared to that measured with the
D136A mutant [12] (Figure 1a). Surprisingly, SR121463, an
inverse agonist, hardly decreased the constitutive activities of
R137C and R137L receptor compared to the D136A receptor.
This absence of large effect was not due to a loss of affinity since
competition experiments of [
3H]AVP binding showed that
SR121463 exhibits similar inhibition constant (Ki) for the wild-
type and the mutant receptors (Table 1).
Then, we have examined the agonist-dependent receptor
activity in cAMP assay. Similarly, R137C and R137L receptors
presented a weak sensitivity to AVP stimulation, compared to the
wild-type receptor, dose-response curves with R137C and R137L
mutants exhibiting a very significant rightward shift of AVP
potency and a lower efficiency (Figure 1b and Table 1). The
differences between WT and mutants were not due to lower
affinities of AVP for R137C and R137L mutants as verified by
saturation experiments with [
3H]AVP (Table 1). Of note, the
AVP-induced cAMP production was inhibited by increasing
concentrations of SR121463 (Figure 1c). Taken together, our
data indicate that R137C and R137L mutations did not change
the binding properties of V2 receptors but they largely affect the
agonist-promoted G protein activation. As such, it differs from the
super activity of D136A receptor [12].
Next, we examined the physical association of V2 receptors with
b-arrestins, the recruitment of b-arrestins being involved in V2
receptor desensitization [13]. For this, bioluminescence resonance
energy transfer (BRET) experiments [9,14,15] were performed
using V2 chimeric receptors and b-arrestins respectively fused to
the luciferase from Renilla reniformis (Rluc) and the yellow
fluorescent protein (YFP) (Figure 2a). In this configuration, we
did not observe any significant basal BRET signal (Figure 2b). By
contrast, AVP stimulation induced a significant BRET signal
indicating b-arrestin 1 recruitment. Of note the recruitment
observed with R137C and R137L receptors is about 50% less than
with the wild-type receptor (Figure 2b) despite a slightly higher
expression determined by luminescence measurements (figure 2c).
Dose-response experiments of AVP-induced BRET showed right-
shifted curves with R137C and R137L mutants compared to the
wild-type receptor (Figure 2d and Table 1). This observation is
consistent with dose-response results in cAMP assay. Moreover,
kinetics analysis of AVP-induced BRET increase indicates that t1/2
values of b-arrestin 1 recruitment with V2 mutants are twice
greater than that obtained with the wild-type receptor (Figure 2e
and Table 1). It is noteworthy that the absence of a significant
BRET signal with the D136A receptor is most probably due to a
Figure 1. Coupling properties of the wild-type and mutants receptors. a, Basal, agonist induced and antagonist-inhibited cAMP
accumulation was measured on cos 7 cells expressing wild-type or mutants receptors. Values of cAMP accumulation were normalized to the number
of receptors expressed at the surface of the cells determined by ligand binding [3H]AVP. b, AVP dose-response experiments performed on cells
expressing wild-type, R137C or R137L V2 receptor. c, effect of an inverse agonist, SR121463, on AVP-induced stimulation.
doi:10.1371/journal.pone.0008383.g001
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previously shown [12]. Moreover similar results were obtained
with b-arrestin 2 and in HEK293 cell line indicating an absence of
b-arrestin or cell line specificity (data not shown).
Given the constitutive production of cAMP with the mutant
receptors, and because V2 receptors have been shown to undergo
b-arrestin dependent internalization after their activation {Oakley,
1999 #621}, we were expecting a constitutive recruitment of b-
arrestins. Our results were also at variance with those previously
reported [16], the discrepancy between the two studies being
possibly linked to the level of mutant receptors trapped into the
cells, leading to a variation in the luminescent signal in the basal
conditions. We then performed BRET experiments with the
reverse configuration, i.e. V2-YFP receptor and Rluc-b-arrestin 1
(Figure 3). Interestingly, this configuration led us to measure a
significant constitutive BRET signal between b-arrestin 1 and
R137C or R137L mutants Figure 3b and c), but not with the wild-
type V2 receptor (Figure 3a), indicating a basal recruitment of b-
arrestin 1 by V2 mutants which could be associated with their
constitutive activity. In addition, in this configuration, the BRET
saturation experiments indicated that AVP-promoted b-arrestin 1
recruitment reveals first, a lower AVP induced-recruitment of b-
Table 1. Pharmacological properties of the R137C and R137L V2 receptors compared to the those of the wild-type and D136A
receptor.
Affinity of AVP
Affinity of
SR121463
AVP-induced cAMP
production
AVP-induced BRET increase between V2-Rluc and b-arrestin
1-YFP
Receptor Kd (nM) Ki (nM) EC50 (nM) BRETmax T1/2 (min) EC50 (nM)
Wild-type 2.6160.44 1.260.11* 0.4060.09 9965 8.161.8 3.361.3
R137C 2.860.18 1.3460.32 .100* 47621 6 . 1 64.7 46.6619.5
R137L 3.7160.17 2.4160.86 .30* 53631 7 . 4 65.6 43.3615.6
D136A 0.4060.27 0.7960.18 0.560.15 ** 1062 N.D. N.D.
*: the values cannot be determined since the curves do not reach a plateau.
**: values from [19].
doi:10.1371/journal.pone.0008383.t001
Figure 2. b-arrestin 1 recruitment to V2R studied by BRET. a, For BRET measurements, V2 receptors and b-arrestin 1 were fused to Rluc and
YFP proteins, respectively, and co-expressed in COS-7 cells treated or not with AVP for 45 minutes. b, AVP-induced b-arrestin 1 recruitment to either
V2 wild-type, R137C, R137L or D136A mutants. Data are means6S.E.M of three independent experiments. c, Expression levels of BRET partners
determined by Rluc luminescence and YFP fluorescence d, Dose-response of AVP-induced BRET after AVP stimulation for 45 minutes. e, BRET time-
course: BRET increase between V2 receptors and b-arrestin 1 after AVP stimulation (1 mM) at the indicated time. Data are means6S.E.M of three
independent experiments.
doi:10.1371/journal.pone.0008383.g002
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and second, a lower affinity of b-arrestin 1 for the V2 receptor
mutant after AVP stimulation (Figure 3d). The BRET50 for the
different curves are 0.20, 1.85, 1.12 for the WT, R137C and
R137L, respectively. Taken together, these data indicate that, by
contrast to the wild-type receptor, R137C and R137L mutants
exhibit a constitutive b-arrestin recruitment but they also exhibit a
lower sensitivity to AVP stimulation in b-arrestin recruitment.
Discussion
NSIAD is a rare disease recently described. Two features are
particularly interesting, regarding the molecular and the physio-
logical aspects. We observe for the R137C and R137L receptors a
correlation between the production of cAMP and b-arrestins
recruitment as well as in the basal or AVP-induced stimulation
conditions. Both receptors exhibit a rightward shift of the AVP-
induced dose-response curves of cAMP production and b-arrestins
recruitment. These data are consistent with those reporting that
the recruitment of b-arrestin is consecutive to V2 receptor
activation [13]. Although R137C and R137L V2 mutants exhibit
G protein constitutive activities as the D136A receptor, they
displayed different properties. By contrast to the D136A receptor
which exhibits a large constitutive activity sensitive to inverse
agonist and a super activity when stimulated with agonists [12],
the R137C and R137L mutants show small amplitude constitutive
activities which are also weakly sensitive to the inverse agonist.
This observation is consistent with patient’s insensitivity to the
administration of inverse agonist [4]. These mutants are thus in an
almost blocked conformation. By contrast the small AVP-induced
stimulation of receptor is completely inhibited by inverse agonist
suggesting that the receptors can also adopt a second more flexible
conformation. The existence of two conformations may be
responsible for the discrepancies observed in the BRET signal
with the two BRET configurations used since energy transfer is
dependent on the distance or the orientation of the donor and the
acceptor.
NSIAD exhibits a large phenotypic variability by contrast to the
cNDI pathology characterized by a clear phenotype. Indeed if few
patients have been identified at a early stage [3,8], others were at a
later one [6]. This variability is not reliable to the nature of the
mutation since only two mutations, R137C in eight cases and
R137L in one case, have been identified. These two mutants
exhibit weak constitutive activities suggesting that it can be
compatible with life as soon as water balance is maintained in a
narrow window. In such conditions, the detection of the pathology
is thus difficult. However, environmental factors (heatwave,
sports…) can be at the origin of behavioural modifications
inducing water intake and then water overload, leading to more
severe symptoms. Moreover AVP is detectable in some patients
with NSIAD [8] while it is not in others. The presence or the
absence of AVP should not have important consequences on the
phenotype since the R137C and R137L receptors exhibit only a
weak AVP-induced activity
Finally the two mutations responsible for NSIAD contrast with
the high number of mutations in cDNI. It suggests that mutations
such as D136A which exhibit in vitro very high constitutive activity
and therefore which should confer more severe symptoms have
never been reported since they are probably not compatible with
life. However one can speculate that other mutations should be
identified. Indeed the DRY/H motif in the third transmembrane
domain is engaged with residues of the sixth transmembrane
domain in an ionic lock which prevents receptor activation [17].
Therefore mutations in the sixth transmembrane domain can
result in the expression of the NSIAD syndrome.
In conclusion, the expression of the R137C and R137L mutants
result in a background production of cAMP leading to a
constitutive water reabsoption. Since the activity of the receptor
is hardly regulated by vasopressin or by inverse agonist, it suggests
that these receptors are in a blocked conformation preventing any
good adaptation of the antidiuretic activity to environmental
stimulation. Therefore it suggests the importance of environmental
parameters in the expression of the disease. Although the
regulation of the water balance is compatible with life in normal
conditions in patient having NSIAD, the repeat of situations
leading to water overloading can severely affect patient health.
The importance of the environmental parameters can then be
responsible in part for the phenotypic variability of NSIAD. The
identification of NSIAD syndrome is recent with a small hindsight,
but the establishment of precise criteria for early diagnosis of the
disease is therefore necessary.
Materials and Methods
Cell Culture
Cos-7 cell lines were maintained in culture in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal calf serum
and 100 units/mL penicillin and streptomycin in an atmosphere
Figure 3. BRET-saturation of basal and AVP-induced b-arrestin 1 recruitment. a, The inverse configuration of BRET was used for saturation
experiments where V2 receptors and b-arrestin 1 were fused to YFP and Rluc proteins, respectively. BRET measurements were performed in COS-7
cells co-expressing a constant amount of Rluc-b-arrestin 1 with the increasing level of V2-YFP receptors: the wildtype (a), R137C (b) or R137L (c) in the
absence (v) or presence () of AVP stimulation (1 mM) for 45 minutes. d, AVP-induced BRET increase compared between V2R wildtype, R137C and
R137L mutants. BRET50 are 0.2, 1.84 and 1.12 for the wild-type, R137C and R137L receptors, respectively. Each panel corresponds to three
independent experiments.
doi:10.1371/journal.pone.0008383.g003
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transfected by electroporation with various concentration of vector
coding for human V1a receptor and empty vector to a final
amount of 10 ı ´g. Under this condition, the expression level is in the
range of 0.5 to 2 pmol/mg protein. Cells were also transfected
with Lipofectamine 2000 (Invitrogen) according to the recom-
mandations of the manufacturer.
Membrane Preparations
Culture dishes of Cos-7 expressing the human vasopressin V2
receptors were washed twice in PBS without calcium and
magnesium, and cold lysis buffer (15 mM Tris:HCl, 2 mM
MgCl2, 0.3 mM EDTA, pH 7.4) was added. Cells were scraped
with a rubber, homogenized, and centrifuged at 100 g for 5 min at
4uC. Supernatants were recovered and centrifuged at 44 000 g for
30 min at 4uC. Pellets were resuspended in a suspension medium
(50 mM Tris:HCl, 5 mM MgCl2, pH 7.4) centrifuged at 44 000 g
for 30 min at 4uC. Pellets were resuspended in an appropriate
volume of the same buffer. For each membrane preparation,
protein content was evaluated, and membranes were then
aliquoted and frozen in liquid nitrogen.
Binding Experiments on Membrane
Binding assays were performed at 30uC using [
3H]AVP as the
radioligand and 5–15 mg of membrane proteins per assay.
Affinities of [
3H]AVP for the various mutants were determined
in saturation experiments using concentrations ranging from 0.2 to
15 nM. Affinities for other ligands were determined fro compe-
tition experiments using 2–5 nM [
3H]AVP as radioligand. The
concentration of the unlabeled ligands varied from 1 pM to 1 mM.
Non specific binding was determined in the presence of
vasopressin (1 mM). Bound tritiated vasopressin ([
3H]AVP)
fractions were separated from the free tritiated vasopressin by
filtration. We used Whatman GF-C filters preincubated in bovine
serum albumin (10 mg/mL). Filtration was performed on a
Brandel apparatus. Radioactivity on the filters was counted on a
beta-counter Tri-carb 2100TR (Perkin-Elmer Life and Analytical
Sciences). The ligand binding data were analyzed by nonlinear
least-squares regression using the computer program Graphpad
Prism (GraphPad Software). All assays were performed in
triplicate on at least three separate batches of electroporated cells.
Binding Experiments on Cells
Experiments were performed in a 96 well plate format. Cells
which were rinsed twice with a cold isotonic saline buffer (NaCl,
146 mM; KCl, 0.42 mM; MgCl2, 0.5 mM, CaCl2, 1 mM; Hepes,
2 mM), have been incubated for 4 hours at 4uC in the presence of
10 nM [
3H]AVP, 1 mM phenylalanine and in the presence or the
absence of an excess of unlabeled AVP (1 mM). Cells were then
rinsed three times with cold isotonic saline buffer and 100 mlo f
NaOH (0.1N) was added in each well. The lysates were transferred
in radioactivity counting vial. NaOH (0.1 N) was used to rinse
each well and transfer to the counting vial. 200 ml of HCl (0.1 N)
were added in counting vial to neutralized NaOH and
radioactivity was counted on beta-counter Tri-carb 2100TR
(Perkin-Elmer Life and Analytical Sciences).
cAMP measurements. Experiments were performed as
previously described Briefly activation/inhibition of cAMP
pathways by AVP receptor agonists or antagonists, was
determined using cAMP dynamic kits (Cisbio Bioassays,
Bagnols-sur-Ce `ze, France) according to the recommendations of
the manufacturer. Cells were incubated in the presence of a
phosphodiesterase inhibitor, Ro-20-1724 (Calbiochem,
Darmstadt, Germany) to prevent cAMP degradation. The basal
cAMP productions were measured after a 5 h-long accumulation
period. Agonist activations or antagonist inhibitions were
performed as previously described [18]. Dose dependent curves
were fitted with Graphpad Prism software. The experiments were
repeated at least three times on different cultures. Normalization
was performed as indicated in the figure legends, either as a
percentage of the maximal value or as a percentage of the
maximal value for AVP when comparisons were necessary.
BRET measurements. For BRET experiments, V2
receptors and b-arrestin 1 were fused to Rluc and YFP proteins
and co-expressed in COS-7 cells. Adherent cells were cultured in
96-well plates and 48 hours after transfection cells were first
stimulated with AVP in DMEM-serum free supplemented by BSA
0.1% and then washed with twice PBS. BRET measurements were
performed in PBS in 50 ml final volume after addition of
coelenterazine h (5 mM) using the Mithras LB940, as previously
reported [15].
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